Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Sabrina Heltz, a director of Viemed Healthcare, Inc. (VMD), reported equity awards and changes in beneficial ownership in August 2025. The Form 4 shows grants and vesting events: on 08/19/2025 she was granted 15,029 restricted stock units (RSUs) that vest on 08/19/2026 and 3,757 phantom share units that vest on 08/19/2026. On 08/20/2025 a previously awarded 15,732 RSUs vested and were acquired, and after the reported transactions she beneficially owned 67,491 common shares. Phantom shares pay cash based on the issuer's share price at vesting. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Jerome Cambre, Vice President of Sales at Viemed Healthcare, Inc. (VMD), reported two open-market sales of common shares on 08/13/2025. He sold 1,580 shares at $7.33 and 3,300 shares at $7.32, a total of 4,880 shares. Following these transactions his beneficial ownership is reported as 84,191 shares. The filing was signed by an attorney-in-fact on 08/14/2025. No derivative securities were reported on this Form 4.
Michael Moore, President of Viemed Healthcare (VMD), reported an insider sale. The Form 4 shows a sale of 50,090 common shares on 08/12/2025 at a price of $7.33 per share. After the transaction Moore directly owns 126,343 shares and indirectly beneficially owns 1,722,614 shares through Moore Faster LLC. The filing discloses the sale but provides no context about volume relative to total outstanding shares.
Michael Moore, President of Viemed Healthcare (VMD), filed an amended Form 4 to correct his reported holdings after a sale. The amendment records a disposal of 8,948 common shares tied to the market closing price on 01/29/2025 with a per-share value shown as $8.28. The corrected post-transaction beneficial ownership is 176,433 shares, amended from an earlier reported 177,433 shares. The filing states the original error affected a prior Form 4 filed July 1 and that subsequent filings will reflect the corrected balance.
Viemed Healthcare, Inc. filed a Form S-8 to register an additional 412,351 common shares for issuance under the Viemed Healthcare, Inc. 2024 Long Term Incentive Plan, as amended. The amendment adding these shares was approved by shareholders at the companys 2025 annual meeting on June 5, 2025. Upon effectiveness, the total shares available for issuance under the 2024 Plan will be 7,904,757. The filing incorporates by reference a prior S-8 filed on August 12, 2024 (File No. 333-281502). The registrant is identified as an accelerated filer and lists British Columbia as its jurisdiction of incorporation and Lafayette, Louisiana as its principal executive office.
Viemed Healthcare, Inc. (VMD) filed an 8-K to announce the closing of its acquisition of Lehan’s Medical Equipment, a privately held home medical equipment provider based in DeKalb, Illinois. The transaction consists of a $26 million base purchase price, subject to customary adjustments, plus an estimated $2.2 million contingent consideration.
The company stated that it will update its full-year 2025 guidance to reflect Lehan’s expected contribution when it reports Q2 2025 earnings (period ended June 30, 2025). No immediate changes to guidance or pro-forma financials were included in this filing; the related press release is furnished as Exhibit 99.1 and deemed “furnished,” not “filed,” under the Exchange Act.
For investors, the filing signals completion of a strategic bolt-on acquisition that expands VMD’s geographic reach into Illinois and broadens its home medical equipment offerings. The cash outlay and contingent payments may affect near-term liquidity, while future revenue impact will be clarified with the forthcoming guidance update.